Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239447 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
- 11
- Study locations
NCT00239447 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 131 participants, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT00239447, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
- 11
- Study locations
Study Summary
Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
Conditions Studied
Interventions
- DRUG Tiotropium
- DEVICE HandiHaler
- DEVICE Respimat SMI
Study Locations (11)
California
- Boehringer Ingelheim Investigational Site - San Diego
- San Jose Clinical Research - San Jose
- Boehringer Ingelheim Investigational Site - Stockton
Arkansas
- Division of Pulmonary and Critical Care Medicine - Little Rock
Colorado
- National Jewish Medical and Research Center - Denver
Louisiana
- LSU MC-Sheveport - Shreveport
Minnesota
- Minisota Lung Center - Minneapolis
North Carolina
- Wake Forest University School of Medicine - Winston-Salem
South Carolina
- Spartanburg Medical Research - Spartanburg
Washington
- Boehringer Ingelheim Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2002-11-26 |
| Est. Completion | 2004-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239447
The ClinicalTrials.gov registry entry for NCT00239447 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (87% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which Tiotropium is the first listed.
NCT00239447 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Arkansas, Colorado.
Frequently Asked Questions
What is clinical trial NCT00239447 about?
NCT00239447 is a clinical study titled "Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD". Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
What is the current status of trial NCT00239447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2002-11-26. Estimated completion is 2004-04-29.
What conditions does trial NCT00239447 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00239447?
The interventions under investigation include: Tiotropium (DRUG), HandiHaler (DEVICE), Respimat SMI (DEVICE).
Who is sponsoring clinical trial NCT00239447?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00239447 being conducted?
This trial has 11 study locations across Arkansas, California, Colorado, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.